AVERSA, ZAIRA
 Distribuzione geografica
Continente #
NA - Nord America 1.300
EU - Europa 220
AS - Asia 167
SA - Sud America 9
AF - Africa 5
OC - Oceania 2
Totale 1.703
Nazione #
US - Stati Uniti d'America 1.295
CN - Cina 86
IN - India 80
IT - Italia 74
FI - Finlandia 42
UA - Ucraina 36
SE - Svezia 27
GB - Regno Unito 15
IE - Irlanda 10
BE - Belgio 9
AR - Argentina 6
CA - Canada 5
DE - Germania 3
RO - Romania 3
ZA - Sudafrica 3
BJ - Benin 2
CL - Cile 2
NZ - Nuova Zelanda 2
BG - Bulgaria 1
PE - Perù 1
SA - Arabia Saudita 1
Totale 1.703
Città #
Fairfield 239
Woodbridge 128
Chandler 106
Houston 94
Ashburn 87
Wilmington 84
Seattle 83
Beijing 75
Cambridge 72
Plano 40
Princeton 40
Ann Arbor 36
Rome 33
San Paolo di Civitate 24
Millbury 23
Lawrence 20
San Diego 19
Boston 17
Andover 15
Jacksonville 15
Dearborn 10
Dublin 10
Brussels 9
Federal 6
San Mateo 6
San Jose 5
Toronto 5
Falls Church 4
Hefei 4
Boardman 3
Frankfurt am Main 3
Muizenberg 3
Norwalk 3
Auburn Hills 2
Fasano 2
Hounslow 2
London 2
Marino 2
Southwark 2
Zhengzhou 2
Auckland 1
Brandizzo 1
Callao 1
Chongqing 1
Des Moines 1
Fremont 1
Genova 1
Helsinki 1
Indiana 1
Jinan 1
Lappeenranta 1
Laurel 1
Los Angeles 1
Nanchang 1
Nanjing 1
Provo 1
Redmond 1
Santiago 1
Sofia 1
Trento 1
Wellington 1
Westminster 1
Wuhan 1
Totale 1.358
Nome #
β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia 83
Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. 77
Prevention and treatment of cancer cachexia: New insights into an old problem 71
Consensus definition of sarcopenia, cachexia and pre-cachexia; joint document elaborated by Special Interest Groups (SIG) “Cachexia-Anorexia in Chronic Wasting Diseases” and “Nutrition in Geriatrics”. 71
PPARβ/δ regulates glucocorticoid- and sepsis-induced FOXO1 activation and muscle wasting 68
Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients 62
null 59
The conundrum of pre-cachexia existence 58
Acetylation and deacetylation--novel factors in muscle wasting. 58
C/EBPβ regulates dexamethasone-induced muscle cell atrophy and expression of atrogin-1 and MuRF1. 57
Vitamin D and VDR in cancer cachexia and muscle regeneration 56
Multiple muscle wasting-related transcription factors are acetylated in dexamethasone-treated muscle cells. 56
CaMKII activity is reduced in skeletal muscle during sepsis 55
Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. 55
Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. 54
Molecules modulating gene transcription during muscle wasting in cancer, sepsis, and other critical illness. 53
null 50
null 50
Loss of muscle strength during sepsis is in part regulated by glucocorticoids and is associated with reduced muscle fiber stiffness 50
Cortisol and the muscle-bone axis 49
β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy 46
Nutritional support in cancer 40
La nutrizione artificiale nel paziente oncologico 40
Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. 40
Statins, Coenzyme Q10, and Cachexia: What's the Link? 36
Livelli sierici di leptina e anoressia in pazienti in trattamento dialitico continuato 30
Attività serino-proteasica muscolare nella cachessia neoplastica sperimentale 29
Molecular mechanisms underlyng muscle loss in patients undergoing liver transplantation 25
Beta-hydroxy-beta-methylbutyrate prevents weight and muscle loss in cancer cachexia 25
New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway' 24
Nutritional and metabolic support in hematologic malignancies and hemotopoietic stem cell trasplantation 24
Body mass index (BMI) is related to autonomic nervous system activity as measured by heart rate variability (HRV) 24
L’ espressione genica della miostatina è aumentata dalla presenza di neoplasia 20
Meccanismi molecolari e massa muscolare in pazienti sottoposti a trapianto di fegato 20
Nuove frontiere della nutrizione clinica nella malattia oncologica 19
Possibilità di impiego della farmaconutrizione 17
La cachessia neoplastica: conoscerla per prevenirla e contrastarla 17
Il paziente in emodialisi: anoressia e ghrelina 16
La somministrazione di idrossi-metil-butirrato previene la perdita di peso e di muscolo in un modello sperimentale di cachessia neoplastica 15
Pharmacological inhibition of the ubiquitin/proteasome ATP-dependent system does not prevent muscle wasting in experimental cancer cachexia 15
Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting 8
Cancer-induced muscle wasting: latest findings in prevention and treatment 7
Autophagy is induced in the skeletal muscle of cachectic cancer patients 3
Totale 1.732
Categoria #
all - tutte 4.111
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.111


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019218 0 0 0 0 0 0 0 0 3 44 103 68
2019/2020498 70 17 3 21 46 61 60 58 49 62 41 10
2020/2021113 14 17 5 17 1 4 0 17 15 9 11 3
2021/2022363 1 32 46 4 59 1 9 37 27 34 26 87
2022/2023317 76 69 7 30 38 31 1 9 37 4 6 9
2023/202464 14 31 3 6 4 3 1 2 0 0 0 0
Totale 1.732